Athira Pharma Inc reports results for the quarter ended September 30 - Earnings Summary

LeonaBio

08/11/2024 21:08

* Athira Pharma Inc  ATHA.OQ  reported a quarterly adjusted
loss
of 75 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -87 cents.  The mean expectation of
five analysts for the quarter was for a loss of 71 cents per
share. Wall Street expected results to range from -80 cents
to -50 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Athira Pharma Inc's reported EPS for the quarter was a
loss
of 75 cents​.
    * The company reported a quarterly loss of $28.7 million.
    * Athira Pharma Inc shares had risen by 68.2% this
quarter and
lost 69.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 16.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Athira Pharma Inc
is $0.55 
This summary was machine generated from LSEG data November 8 at
09:07 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.71          -0.75          Missed
 Jun. 30 2024      -0.74          -0.70          Beat
 Mar. 31 2024      -0.79          -0.69          Beat
 Dec. 31 2023      -0.96          -0.71          Beat